{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:23:34Z","timestamp":1790835814109,"version":"4.1.0"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.36368","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T18:08:29Z","timestamp":1473876509000},"page":"508-517","source":"Crossref","is-referenced-by-count":21,"title":["Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin"],"prefix":"10.5551","volume":"24","author":[{"given":"Hsu-Lung","family":"Jen","sequence":"first","affiliation":[{"name":"Division of Cardiology, Cheng-Hsin General Hospital"},{"name":"Institute of Clinical Medicine, National Yang-Ming University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsian","family":"Yin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cheng-Hsin General Hospital"},{"name":"Faculty of Medicine, National Yang-Ming University"},{"name":"Cardiovascular Research Centre, School of Medicine, National Yang-Ming University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital"},{"name":"Institute of Pharmacology, National Yang-Ming University"},{"name":"Cardiovascular Research Centre, School of Medicine, National Yang-Ming University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing-Jong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Research and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital"},{"name":"Institute of Clinical Medicine, National Yang-Ming University"},{"name":"Cardiovascular Research Centre, School of Medicine, National Yang-Ming University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Balakumar P, Jagadeesh G: Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res, 2010; 62: 365-383","DOI":"10.1016\/j.phrs.2010.07.003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Drawnel FM, Archer CR, Roderick HL: The role of the paracrine\/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol, 2013; 168: 296-317","DOI":"10.1111\/j.1476-5381.2012.02195.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Schiffrin EL: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol, 2005; 288: H1037-H1043","DOI":"10.1152\/ajpheart.00677.2004"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Smeets PJ, de Vogel-van den Bosch HM, Willemsen PH, Stassen AP, Ayoubi T, van der Vusse GJ, van Bilsen M: Transcriptomic analysis of PPARalpha-dependent alterations during cardiac hypertrophy. Physiol Genomics, 2008; 36: 15-23","DOI":"10.1152\/physiolgenomics.90296.2008"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwen-hoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M: Cardiac hypertrophy is enhanced in PPAR alpha-\/- mice in response to chronic pressure overload. Cardiovasc Res, 2008; 78: 79-89","DOI":"10.1093\/cvr\/cvn001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Oyekan A: PPARs and their effects on the cardiovascular system. Clin Exp Hypertens, 2011; 33: 287-293","DOI":"10.3109\/10641963.2010.531845"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA: Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther, 2007; 321: 165-171","DOI":"10.1124\/jpet.106.116871"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I: Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressureoverloaded rat hearts. Clin Sci (Lond), 2002; 103 (Suppl 48): 284S-288S","DOI":"10.1042\/CS103S284S"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M: Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol, 2006; 41: 318-329","DOI":"10.1016\/j.yjmcc.2006.05.013"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Huang WP, Yin WH, Chen JW, Jen HL, Young MS, Lin SJ: Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. Eur J Clin Invest, 2009; 39: 775-783","DOI":"10.1111\/j.1365-2362.2009.02176.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Irukayama-Tomobe Y, Miyauchi T, Sakai S, Kasuya Y, Ogata T, Takanashi M, Iemitsu M, Sudo T, Goto K, Yamaguchi I: Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway. Circulation, 2004; 109: 904-910","DOI":"10.1161\/01.CIR.0000112596.06954.00"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Irukayama-Tomobe Y, Miyauchi T, Kasuya Y, Sakai S, Goto K, Yamaguchi I: Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes. J Cardiovasc Pharmacol, 2004; 44 (Suppl 1): S358-S361","DOI":"10.1097\/01.fjc.0000166303.33313.01"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Le K, Li R, Xu S, Wu X, Huang H, Bao Y, Cai Y, Lan T, Moss J, Li C, Zou J, Shen X, Liu P: PPAR\u03b1 activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. Arch Biochem Biophys, 2012; 518: 71-78","DOI":"10.1016\/j.abb.2011.11.024"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P: Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-\u03b1 partly via preventing p65-NF\u03baB binding to NFATc4. Mol Cell Endocrinol, 2013; 370: 103-112","DOI":"10.1016\/j.mce.2013.03.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Planavila A, Laguna JC, V\u00e1zquez-Carrera M: Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta, 2005; 1687: 76-83","DOI":"10.1016\/j.bbalip.2004.11.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Park M, Sweeney G: Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev, 2013; 18: 631-644","DOI":"10.1007\/s10741-012-9337-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Goldstein BJ, Scalia RG, Ma XL: Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med, 2009; 6: 27-35","DOI":"10.1038\/ncpcardio1398"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med, 2004; 10: 1384-1389","DOI":"10.1038\/nm1137"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20) Fujioka D, Kawabata K, Saito Y, Kobayashi T, Nakamura T, Kodama Y, Takano H, Obata JE, Kitta Y, Umetani K, Kugiyama K: Role of adiponectin receptors in endothelininduced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol, 2006; 290: H2409-H2416","DOI":"10.1152\/ajpheart.00987.2005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21) Yin WH, Chen YH, Wei J, Jen HL, Huang WP, Young MS, Chen DC, Liu PL: Associations between endothelin-1 and adiponectin in chronic heart failure. Cardiology, 2011; 118: 207-216","DOI":"10.1159\/000328780"},{"key":"21","doi-asserted-by":"crossref","unstructured":"24) Balfour JA, McTavish D, Heel RC: Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs, 1990; 40: 260-290","DOI":"10.2165\/00003495-199040020-00007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"25) Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu P, Mito S, Kunisaki M, Tachikawa H, Kodama M, Aizawa Y: Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol, 2006; 10: 378-385","DOI":"10.1016\/j.ijcard.2005.08.061"},{"key":"23","doi-asserted-by":"crossref","unstructured":"26) Takahashi T, Saegusa S, Sumino H, Nakahashi T, Iwai K, Morimoto S, Nojima T, Kanda T: Adiponectin, T-cadherin and tumour necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res, 2005; 33: 236-244","DOI":"10.1177\/147323000503300212"},{"key":"24","doi-asserted-by":"crossref","unstructured":"27) Clarke KJ, Zhong Q, Schwartz DD, Coleman ES, Kemppainen RJ, Judd RL: Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun, 2003; 312: 945-949","DOI":"10.1016\/j.bbrc.2003.11.015"},{"key":"25","doi-asserted-by":"crossref","unstructured":"28) Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, Hildebrandt P: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation, 2005; 112: 1756-1762","DOI":"10.1161\/CIRCULATIONAHA.104.530972"},{"key":"26","doi-asserted-by":"crossref","unstructured":"29) Yin WH, Wei J, Huang WP, Chen JW, Young MS, Lin SJ: Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure. Circ J, 2012; 76: 2139-2147","DOI":"10.1253\/circj.CJ-11-1549"},{"key":"27","doi-asserted-by":"crossref","unstructured":"30) Hattori Y, Hattori S, Kasai K: Globular adiponectin activates nuclear factor-kappaB in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care, 2006; 29: 139-141","DOI":"10.2337\/diacare.29.01.06.dc05-1364"},{"key":"28","doi-asserted-by":"crossref","unstructured":"31) Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K: Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes, 2007; 56: 804-808","DOI":"10.2337\/db06-1405"},{"key":"29","doi-asserted-by":"crossref","unstructured":"32) Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A, 2001; 98: 2005-2010","DOI":"10.1073\/pnas.98.4.2005"},{"key":"30","doi-asserted-by":"crossref","unstructured":"33) Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS: Adiponectin acts in the brain to decrease body weight. Nat Med, 2004; 10: 524-529","DOI":"10.1038\/nm1029"},{"key":"31","doi-asserted-by":"crossref","unstructured":"34) Ara\u00fajo JP, Louren\u00e7o P, Rocha-Gon\u00e7alves F, Ferreira A, Bettencourt P: Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail, 2009; 11: 567-572","DOI":"10.1093\/eurjhf\/hfp046"},{"key":"32","doi-asserted-by":"crossref","unstructured":"35) Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M: Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J, 2009; 73: 1067-1073","DOI":"10.1253\/circj.CJ-08-1026"},{"key":"33","doi-asserted-by":"crossref","unstructured":"36) Matsumoto M, Lee-Kawabata M, Tsujino T, Naito Y, Ezumi A, Sakoda T, Ohyanagi M, Shimomura I, Masuyama T: Decrease in serum adiponectin levels in response to treatment predicts good prognosis in acute decompensated heart failure. J Clin Hypertens (Greenwich), 2010; 12: 900-904","DOI":"10.1111\/j.1751-7176.2010.00368.x"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/5\/24_36368\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:48:41Z","timestamp":1498330121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/5\/24_36368\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.36368","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}